TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will host a key opinion leader (KOL) webinar on “

Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes

” on Wednesday, July 27, 2022 at 10:00 am Eastern Time.

The webinar will feature a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who will discuss the use of RNA-based platform technologies in drug discovery.

The HTG Therapeutics team will introduce their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated approach to small molecule drug discovery. They will also discuss how their therapeutically-agnostic approach can be applied to render increasingly de-risked small molecule early development drug candidates and a better understanding of diseases and treatment options for patients.

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

A live question and answer session will follow. To register for the event, please click

here

.

Dr. Spitale currently serves as the Associate Director and Associate Dean of Research in the School of Pharmacy & Pharmaceutical Sciences at University of California, Irvine (UCI). After joining UCI Pharmaceutical Sciences Department as an Assistant Professor in 2014, he was promoted to Associate Professor in 2018, and rose to the ranks of Professor in 2020. In this time, Dr. Spitale’s research has focused on developing novel chemical and bioinformatic approaches toward understanding the role of RNA structure and function in normal biology as well as disease. Beyond his research accomplishments, he has been an active presence in the UCI community as the Director of the RNA Club and its annual symposium, a co-founder of the Chemical and Systems Biology Club and the faculty advisor for the Pharm Sci undergraduate student council. He is also a vital part of the development of the planned School of Pharmacy and Pharmaceutical Sciences, having served on the Pharmacy Planning group responsible for creating proposals to the UCI Senate, UC System, and the Accreditation Council for Pharmacy Education (ACPE). Dr. Spitale received his Ph.D. degree in Chemistry at the University of Rochester in 2009, as an Elon Huntington Hooker Fellow with Professor Joseph Wedekind. He then transitioned to postdoctoral studies at Stanford University and was awarded the A.P. Giannini Fellowship to support his research with Professor Howard Chang.

About HTG:


HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit

www.htgmolecular.com

.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding HTG’s proprietary transcriptome-informed drug discovery platform and how HTG’s therapeutically-agnostic approach can be applied to render increasingly de-risked small molecule early development drug candidates and a better understanding of diseases and treatment options for patients. Words such as “can,” “designed to,” “believe,” “will,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the HTP or our RNA platform technology may not perform as expected or provide the benefits that we expect; risks associated with our ability to develop and commercialize our products, including HTP; the risk that HTP or our other products and services may not be adopted by biopharmaceutical companies or other customers as anticipated; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the SEC on May 12, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

HTG Investor Contact:

Ashley Robinson

LifeSci Advisors

Phone: (617) 430-7577

Email: [email protected]